 Gregory Kinney
Concepts (389)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 52 | 2024 | 929 | 5.810 |
Why?
| | Coronary Artery Disease | 27 | 2023 | 607 | 1.930 |
Why?
| | Tomography, X-Ray Computed | 40 | 2023 | 2344 | 1.750 |
Why?
| | Diabetes Mellitus, Type 1 | 37 | 2022 | 3250 | 1.690 |
Why?
| | Smokers | 16 | 2023 | 129 | 1.570 |
Why?
| | Smoking | 25 | 2023 | 1392 | 1.480 |
Why?
| | Cannabis | 8 | 2023 | 383 | 1.400 |
Why?
| | Forced Expiratory Volume | 24 | 2024 | 476 | 1.200 |
Why?
| | Pulmonary Emphysema | 11 | 2023 | 280 | 1.180 |
Why?
| | Bronchiectasis | 7 | 2023 | 107 | 1.080 |
Why?
| | Calcinosis | 17 | 2015 | 242 | 1.010 |
Why?
| | Respiratory Function Tests | 11 | 2021 | 523 | 0.910 |
Why?
| | Diabetic Ketoacidosis | 3 | 2022 | 159 | 0.880 |
Why?
| | Hyperlipidemias | 2 | 2023 | 123 | 0.880 |
Why?
| | Lung | 20 | 2023 | 3595 | 0.840 |
Why?
| | Marijuana Smoking | 3 | 2022 | 223 | 0.830 |
Why?
| | Dronabinol | 3 | 2021 | 118 | 0.810 |
Why?
| | Cardiovascular System | 1 | 2023 | 126 | 0.810 |
Why?
| | Diabetic Angiopathies | 11 | 2016 | 244 | 0.710 |
Why?
| | Volatilization | 1 | 2019 | 49 | 0.690 |
Why?
| | Diabetes Mellitus, Type 2 | 5 | 2023 | 2098 | 0.680 |
Why?
| | Middle Aged | 79 | 2023 | 26873 | 0.680 |
Why?
| | Nebulizers and Vaporizers | 1 | 2019 | 78 | 0.670 |
Why?
| | Cannabinoids | 4 | 2023 | 115 | 0.650 |
Why?
| | Spirometry | 14 | 2024 | 225 | 0.600 |
Why?
| | Risk Factors | 35 | 2023 | 8658 | 0.590 |
Why?
| | Cardiovascular Diseases | 5 | 2023 | 1731 | 0.590 |
Why?
| | Air Pollution | 1 | 2019 | 170 | 0.580 |
Why?
| | Coronary Vessels | 7 | 2021 | 230 | 0.570 |
Why?
| | Marijuana Abuse | 1 | 2019 | 212 | 0.570 |
Why?
| | Female | 96 | 2023 | 59720 | 0.570 |
Why?
| | Humans | 120 | 2024 | 115222 | 0.570 |
Why?
| | Male | 88 | 2023 | 55814 | 0.540 |
Why?
| | Vascular Calcification | 5 | 2019 | 107 | 0.520 |
Why?
| | Disease Progression | 24 | 2021 | 2390 | 0.510 |
Why?
| | 1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2016 | 21 | 0.510 |
Why?
| | Risk Assessment | 8 | 2019 | 2981 | 0.500 |
Why?
| | Aged | 38 | 2022 | 19136 | 0.470 |
Why?
| | Cohort Studies | 28 | 2023 | 4917 | 0.470 |
Why?
| | Adult | 50 | 2023 | 30711 | 0.420 |
Why?
| | Prospective Studies | 24 | 2023 | 6245 | 0.410 |
Why?
| | Atherosclerosis | 4 | 2023 | 341 | 0.380 |
Why?
| | Coronary Disease | 7 | 2010 | 347 | 0.380 |
Why?
| | Pulmonary Artery | 4 | 2022 | 1032 | 0.360 |
Why?
| | Emphysema | 2 | 2023 | 110 | 0.360 |
Why?
| | Airway Obstruction | 2 | 2024 | 168 | 0.350 |
Why?
| | Depression | 4 | 2022 | 1137 | 0.340 |
Why?
| | Prevalence | 12 | 2023 | 2257 | 0.330 |
Why?
| | Longitudinal Studies | 8 | 2023 | 2388 | 0.330 |
Why?
| | Lipoproteins | 3 | 2016 | 160 | 0.320 |
Why?
| | Pectoralis Muscles | 3 | 2021 | 13 | 0.320 |
Why?
| | Albuminuria | 4 | 2016 | 164 | 0.310 |
Why?
| | Vital Capacity | 6 | 2023 | 257 | 0.310 |
Why?
| | Calcium | 7 | 2018 | 1104 | 0.310 |
Why?
| | Severity of Illness Index | 15 | 2023 | 2552 | 0.310 |
Why?
| | Young Adult | 15 | 2023 | 10520 | 0.300 |
Why?
| | Metformin | 2 | 2021 | 278 | 0.300 |
Why?
| | Bronchi | 3 | 2022 | 243 | 0.290 |
Why?
| | Case-Control Studies | 14 | 2019 | 3023 | 0.290 |
Why?
| | Marijuana Use | 2 | 2021 | 168 | 0.280 |
Why?
| | Genetic Predisposition to Disease | 7 | 2023 | 2109 | 0.280 |
Why?
| | Predictive Value of Tests | 10 | 2019 | 1816 | 0.270 |
Why?
| | Quality of Life | 4 | 2021 | 2364 | 0.270 |
Why?
| | Tandem Mass Spectrometry | 2 | 2019 | 412 | 0.270 |
Why?
| | Cross-Sectional Studies | 14 | 2024 | 4419 | 0.270 |
Why?
| | Proportional Hazards Models | 6 | 2019 | 1082 | 0.270 |
Why?
| | Hypnotics and Sedatives | 2 | 2019 | 134 | 0.260 |
Why?
| | Body Mass Index | 10 | 2022 | 1968 | 0.250 |
Why?
| | Biomarkers | 11 | 2022 | 3422 | 0.250 |
Why?
| | Cause of Death | 2 | 2018 | 367 | 0.250 |
Why?
| | Antidepressive Agents | 3 | 2019 | 195 | 0.250 |
Why?
| | Pulmonary Diffusing Capacity | 3 | 2023 | 60 | 0.250 |
Why?
| | Plaque, Atherosclerotic | 2 | 2023 | 44 | 0.250 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 2 | 2021 | 180 | 0.240 |
Why?
| | Follow-Up Studies | 11 | 2022 | 4430 | 0.240 |
Why?
| | Artificial Intelligence | 2 | 2023 | 145 | 0.240 |
Why?
| | Renal Insufficiency | 2 | 2016 | 136 | 0.240 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2017 | 294 | 0.240 |
Why?
| | United States | 10 | 2023 | 12256 | 0.230 |
Why?
| | Symptom Flare Up | 2 | 2021 | 38 | 0.230 |
Why?
| | Logistic Models | 12 | 2017 | 1841 | 0.220 |
Why?
| | Aged, 80 and over | 9 | 2022 | 6358 | 0.220 |
Why?
| | Dyspnea | 5 | 2024 | 218 | 0.220 |
Why?
| | Multimorbidity | 1 | 2023 | 30 | 0.220 |
Why?
| | Fibrinogen | 3 | 2014 | 155 | 0.210 |
Why?
| | Adiponectin | 4 | 2016 | 212 | 0.210 |
Why?
| | Propofol | 2 | 2021 | 43 | 0.210 |
Why?
| | Tomography, Emission-Computed | 1 | 2022 | 58 | 0.210 |
Why?
| | Limit of Detection | 2 | 2019 | 53 | 0.210 |
Why?
| | Population Health | 1 | 2023 | 42 | 0.210 |
Why?
| | Umbilical Cord | 2 | 2021 | 80 | 0.200 |
Why?
| | Ketosis | 1 | 2022 | 12 | 0.200 |
Why?
| | Cannabidiol | 1 | 2023 | 60 | 0.200 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2023 | 72 | 0.200 |
Why?
| | Cholesterol | 4 | 2011 | 369 | 0.200 |
Why?
| | Cystatin C | 3 | 2011 | 62 | 0.200 |
Why?
| | Self Report | 3 | 2021 | 699 | 0.190 |
Why?
| | Hallucinogens | 1 | 2023 | 73 | 0.190 |
Why?
| | Molecular Epidemiology | 2 | 2019 | 63 | 0.190 |
Why?
| | Sarcopenia | 1 | 2022 | 63 | 0.190 |
Why?
| | Protective Agents | 1 | 2021 | 38 | 0.190 |
Why?
| | Hand Strength | 2 | 2022 | 95 | 0.190 |
Why?
| | Antirheumatic Agents | 1 | 2023 | 255 | 0.190 |
Why?
| | Genome-Wide Association Study | 5 | 2023 | 1203 | 0.190 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2021 | 76 | 0.180 |
Why?
| | C-Reactive Protein | 2 | 2014 | 363 | 0.180 |
Why?
| | Muscular Atrophy | 1 | 2021 | 78 | 0.180 |
Why?
| | Hepatitis C | 1 | 2023 | 228 | 0.170 |
Why?
| | Diabetic Nephropathies | 2 | 2016 | 234 | 0.170 |
Why?
| | Delirium | 1 | 2021 | 66 | 0.170 |
Why?
| | 2-Propanol | 1 | 2019 | 19 | 0.170 |
Why?
| | Pulmonary Heart Disease | 1 | 2019 | 6 | 0.170 |
Why?
| | Osteoporosis | 1 | 2022 | 225 | 0.170 |
Why?
| | Foam Cells | 1 | 2019 | 13 | 0.170 |
Why?
| | Blood Glucose | 6 | 2022 | 1823 | 0.170 |
Why?
| | Hyperostosis | 1 | 2019 | 5 | 0.170 |
Why?
| | Calibration | 1 | 2019 | 126 | 0.170 |
Why?
| | Genetic Markers | 2 | 2019 | 323 | 0.170 |
Why?
| | Carbon Monoxide | 1 | 2019 | 65 | 0.160 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2019 | 162 | 0.160 |
Why?
| | Regression Analysis | 6 | 2022 | 949 | 0.160 |
Why?
| | Adipose Tissue | 2 | 2017 | 558 | 0.160 |
Why?
| | Anti-Anxiety Agents | 1 | 2019 | 43 | 0.160 |
Why?
| | Sexual and Gender Minorities | 1 | 2021 | 138 | 0.160 |
Why?
| | Diabetes Complications | 2 | 2010 | 212 | 0.160 |
Why?
| | Surface Properties | 1 | 2019 | 387 | 0.160 |
Why?
| | Insulin Resistance | 4 | 2017 | 1079 | 0.150 |
Why?
| | Drug Overdose | 1 | 2022 | 294 | 0.150 |
Why?
| | Lung Diseases, Interstitial | 1 | 2023 | 515 | 0.150 |
Why?
| | Heart Ventricles | 2 | 2020 | 720 | 0.150 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2019 | 162 | 0.150 |
Why?
| | Population Surveillance | 1 | 2021 | 392 | 0.150 |
Why?
| | Environmental Monitoring | 1 | 2019 | 254 | 0.150 |
Why?
| | Vascular Remodeling | 1 | 2019 | 154 | 0.150 |
Why?
| | HIV Infections | 2 | 2023 | 2470 | 0.150 |
Why?
| | Factor Analysis, Statistical | 1 | 2018 | 260 | 0.150 |
Why?
| | Organ Size | 4 | 2021 | 444 | 0.150 |
Why?
| | Phenotype | 4 | 2019 | 2814 | 0.150 |
Why?
| | Urine | 1 | 2017 | 55 | 0.150 |
Why?
| | Polymorphism, Genetic | 3 | 2011 | 618 | 0.150 |
Why?
| | Linear Models | 6 | 2019 | 779 | 0.150 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2023 | 450 | 0.140 |
Why?
| | Obesity | 4 | 2022 | 2525 | 0.140 |
Why?
| | Chronic Disease | 1 | 2023 | 1594 | 0.140 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2017 | 33 | 0.140 |
Why?
| | Blood Pressure | 5 | 2023 | 1540 | 0.140 |
Why?
| | Lung Diseases | 1 | 2023 | 703 | 0.140 |
Why?
| | Bronchitis, Chronic | 1 | 2016 | 17 | 0.140 |
Why?
| | Prenatal Care | 1 | 2019 | 254 | 0.140 |
Why?
| | Anxiety | 2 | 2022 | 846 | 0.130 |
Why?
| | Machine Learning | 1 | 2019 | 318 | 0.130 |
Why?
| | Plasma | 1 | 2017 | 210 | 0.130 |
Why?
| | Comorbidity | 5 | 2021 | 1458 | 0.130 |
Why?
| | Intraoperative Neurophysiological Monitoring | 1 | 2015 | 15 | 0.130 |
Why?
| | Aortography | 1 | 2015 | 50 | 0.130 |
Why?
| | Multivariate Analysis | 5 | 2019 | 1436 | 0.130 |
Why?
| | Arthritis, Rheumatoid | 1 | 2023 | 1002 | 0.120 |
Why?
| | Exercise Tolerance | 3 | 2023 | 214 | 0.120 |
Why?
| | Respiratory System | 1 | 2016 | 138 | 0.120 |
Why?
| | Dexmedetomidine | 1 | 2015 | 45 | 0.120 |
Why?
| | Periodontal Diseases | 1 | 2015 | 57 | 0.120 |
Why?
| | Adiposity | 2 | 2022 | 467 | 0.120 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2019 | 1902 | 0.120 |
Why?
| | Evoked Potentials | 1 | 2015 | 108 | 0.120 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2017 | 141 | 0.120 |
Why?
| | Endothelium, Vascular | 1 | 2021 | 850 | 0.120 |
Why?
| | Respiratory Muscles | 1 | 2014 | 28 | 0.120 |
Why?
| | Evoked Potentials, Somatosensory | 2 | 2015 | 31 | 0.120 |
Why?
| | Health Status | 2 | 2022 | 726 | 0.120 |
Why?
| | Pregnancy Complications | 1 | 2019 | 430 | 0.120 |
Why?
| | Body Composition | 4 | 2021 | 586 | 0.120 |
Why?
| | Subcutaneous Fat | 1 | 2014 | 71 | 0.110 |
Why?
| | Spine | 1 | 2015 | 139 | 0.110 |
Why?
| | Heart | 1 | 2017 | 613 | 0.110 |
Why?
| | Up-Regulation | 1 | 2016 | 812 | 0.110 |
Why?
| | Colorado | 6 | 2021 | 4099 | 0.110 |
Why?
| | Sex Distribution | 5 | 2014 | 337 | 0.110 |
Why?
| | Orthopedic Procedures | 1 | 2015 | 212 | 0.100 |
Why?
| | Aorta | 1 | 2015 | 394 | 0.100 |
Why?
| | Registries | 1 | 2019 | 1765 | 0.100 |
Why?
| | Triglycerides | 2 | 2011 | 472 | 0.100 |
Why?
| | Blood Vessels | 1 | 2013 | 180 | 0.100 |
Why?
| | Occupational Exposure | 1 | 2014 | 256 | 0.100 |
Why?
| | Imaging, Three-Dimensional | 1 | 2015 | 538 | 0.100 |
Why?
| | Haptoglobins | 1 | 2011 | 47 | 0.100 |
Why?
| | Adolescent | 6 | 2022 | 17889 | 0.100 |
Why?
| | Reference Values | 4 | 2023 | 748 | 0.100 |
Why?
| | Hypertension, Pulmonary | 1 | 2022 | 1744 | 0.100 |
Why?
| | Alcohol Drinking | 2 | 2009 | 656 | 0.090 |
Why?
| | Retrospective Studies | 8 | 2021 | 12597 | 0.090 |
Why?
| | Carotid Intima-Media Thickness | 2 | 2023 | 65 | 0.090 |
Why?
| | Walk Test | 2 | 2021 | 52 | 0.090 |
Why?
| | Patient Education as Topic | 2 | 2005 | 683 | 0.090 |
Why?
| | Pediatric Obesity | 1 | 2017 | 493 | 0.090 |
Why?
| | Hypertension | 5 | 2015 | 1060 | 0.090 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 387 | 0.090 |
Why?
| | Diagnostic Techniques, Neurological | 1 | 2009 | 8 | 0.090 |
Why?
| | Coma | 1 | 2009 | 30 | 0.090 |
Why?
| | Facial Nerve | 1 | 2009 | 31 | 0.080 |
Why?
| | Sensitivity and Specificity | 3 | 2022 | 1717 | 0.080 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2009 | 26 | 0.080 |
Why?
| | Kidney | 1 | 2016 | 1188 | 0.080 |
Why?
| | Uric Acid | 1 | 2010 | 148 | 0.080 |
Why?
| | Monitoring, Intraoperative | 1 | 2009 | 39 | 0.080 |
Why?
| | Lymphatic Abnormalities | 1 | 2009 | 18 | 0.080 |
Why?
| | Reproducibility of Results | 5 | 2017 | 2806 | 0.080 |
Why?
| | Respiratory Physiological Phenomena | 2 | 2022 | 29 | 0.080 |
Why?
| | Aortic Diseases | 1 | 2010 | 110 | 0.080 |
Why?
| | Airway Remodeling | 2 | 2021 | 57 | 0.080 |
Why?
| | Surveys and Questionnaires | 7 | 2019 | 4645 | 0.080 |
Why?
| | Diet, Ketogenic | 1 | 2009 | 33 | 0.080 |
Why?
| | Odds Ratio | 4 | 2014 | 958 | 0.080 |
Why?
| | Asymptomatic Diseases | 2 | 2021 | 75 | 0.080 |
Why?
| | Sex Factors | 4 | 2020 | 1722 | 0.080 |
Why?
| | Proteinuria | 1 | 2009 | 78 | 0.080 |
Why?
| | Anesthesia, Intravenous | 2 | 2021 | 9 | 0.080 |
Why?
| | Reproductive History | 1 | 2008 | 12 | 0.080 |
Why?
| | Asthma | 1 | 2021 | 2051 | 0.080 |
Why?
| | Aorta, Thoracic | 1 | 2010 | 261 | 0.080 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 7 | 0.070 |
Why?
| | Face | 1 | 2009 | 168 | 0.070 |
Why?
| | Cystatins | 1 | 2007 | 7 | 0.070 |
Why?
| | Coronary Angiography | 2 | 2014 | 307 | 0.070 |
Why?
| | Inflammation | 2 | 2021 | 2485 | 0.070 |
Why?
| | Radiography | 3 | 2016 | 827 | 0.070 |
Why?
| | Prognosis | 4 | 2021 | 3336 | 0.070 |
Why?
| | Time Factors | 6 | 2015 | 6157 | 0.070 |
Why?
| | Life Style | 1 | 2009 | 431 | 0.070 |
Why?
| | Heart Rate | 1 | 2010 | 705 | 0.070 |
Why?
| | Dietary Fats | 1 | 2009 | 290 | 0.070 |
Why?
| | Incidence | 3 | 2019 | 2324 | 0.070 |
Why?
| | Kidney Diseases | 1 | 2010 | 351 | 0.070 |
Why?
| | Mortality | 2 | 2019 | 287 | 0.070 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 71 | 0.070 |
Why?
| | Contraception | 1 | 2008 | 118 | 0.070 |
Why?
| | Apolipoproteins A | 1 | 2006 | 18 | 0.070 |
Why?
| | Apolipoproteins C | 1 | 2006 | 6 | 0.070 |
Why?
| | Propensity Score | 2 | 2019 | 224 | 0.070 |
Why?
| | Cluster Analysis | 2 | 2019 | 458 | 0.060 |
Why?
| | Receptors, Interleukin-2 | 1 | 2005 | 64 | 0.060 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2010 | 372 | 0.060 |
Why?
| | Internationality | 2 | 2017 | 144 | 0.060 |
Why?
| | Pregnancy | 3 | 2023 | 5525 | 0.060 |
Why?
| | Receptors, IgG | 1 | 2005 | 67 | 0.060 |
Why?
| | Chi-Square Distribution | 3 | 2010 | 498 | 0.060 |
Why?
| | Antihypertensive Agents | 2 | 2007 | 430 | 0.060 |
Why?
| | Abdominal Wall | 1 | 2004 | 24 | 0.060 |
Why?
| | Apolipoprotein C-III | 2 | 2019 | 13 | 0.060 |
Why?
| | Haplotypes | 1 | 2006 | 455 | 0.060 |
Why?
| | Glomerular Filtration Rate | 3 | 2016 | 605 | 0.060 |
Why?
| | Cholesterol, LDL | 1 | 2005 | 308 | 0.060 |
Why?
| | Glucose Clamp Technique | 2 | 2017 | 181 | 0.050 |
Why?
| | Insulin | 3 | 2022 | 2083 | 0.050 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2005 | 349 | 0.050 |
Why?
| | Antigens, CD | 1 | 2005 | 441 | 0.050 |
Why?
| | Nutrition Surveys | 1 | 2024 | 224 | 0.050 |
Why?
| | Genotype | 3 | 2018 | 1781 | 0.050 |
Why?
| | Blood Platelets | 1 | 2005 | 352 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2023 | 125 | 0.050 |
Why?
| | Multifactorial Inheritance | 1 | 2023 | 125 | 0.050 |
Why?
| | Morbidity | 1 | 2022 | 279 | 0.050 |
Why?
| | Radiography, Thoracic | 2 | 2014 | 163 | 0.050 |
Why?
| | Child, Preschool | 3 | 2023 | 9124 | 0.050 |
Why?
| | Muscles | 1 | 2022 | 324 | 0.050 |
Why?
| | Survival Analysis | 2 | 2017 | 1215 | 0.050 |
Why?
| | Lung Volume Measurements | 1 | 2021 | 45 | 0.050 |
Why?
| | Biological Variation, Population | 1 | 2021 | 19 | 0.050 |
Why?
| | Reaction Time | 2 | 2015 | 374 | 0.050 |
Why?
| | Hepacivirus | 1 | 2023 | 233 | 0.050 |
Why?
| | Protective Factors | 1 | 2021 | 87 | 0.050 |
Why?
| | Plethysmography | 1 | 2021 | 104 | 0.050 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2021 | 32 | 0.050 |
Why?
| | Substance Abuse Detection | 1 | 2021 | 62 | 0.050 |
Why?
| | Anesthesia, General | 1 | 2021 | 45 | 0.050 |
Why?
| | Hospitals, Urban | 1 | 2021 | 128 | 0.050 |
Why?
| | Diabetes Mellitus | 1 | 2009 | 909 | 0.050 |
Why?
| | Bayes Theorem | 1 | 2022 | 331 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2021 | 9151 | 0.040 |
Why?
| | Cigarette Smoking | 1 | 2021 | 74 | 0.040 |
Why?
| | Hospitals, Pediatric | 2 | 2017 | 477 | 0.040 |
Why?
| | Homosexuality, Male | 1 | 2021 | 170 | 0.040 |
Why?
| | Oligodeoxyribonucleotides, Antisense | 1 | 2019 | 8 | 0.040 |
Why?
| | Lipids | 2 | 2017 | 587 | 0.040 |
Why?
| | rab4 GTP-Binding Proteins | 1 | 2019 | 8 | 0.040 |
Why?
| | Cytochrome P-450 CYP2B6 | 1 | 2019 | 9 | 0.040 |
Why?
| | Cytochrome P450 Family 2 | 1 | 2019 | 11 | 0.040 |
Why?
| | RNA, Viral | 1 | 2023 | 567 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2019 | 44 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2014 | 1231 | 0.040 |
Why?
| | Birth Weight | 1 | 2022 | 440 | 0.040 |
Why?
| | Multidetector Computed Tomography | 1 | 2019 | 27 | 0.040 |
Why?
| | Exercise | 1 | 2009 | 1644 | 0.040 |
Why?
| | Administration, Inhalation | 1 | 2021 | 641 | 0.040 |
Why?
| | Bronchodilator Agents | 1 | 2021 | 243 | 0.040 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2019 | 41 | 0.040 |
Why?
| | Genomics | 1 | 2023 | 641 | 0.040 |
Why?
| | Bone Density | 1 | 2022 | 432 | 0.040 |
Why?
| | Electroencephalography | 1 | 2021 | 362 | 0.040 |
Why?
| | Europe | 1 | 2019 | 336 | 0.040 |
Why?
| | Systems Biology | 1 | 2018 | 56 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 959 | 0.040 |
Why?
| | Atmospheric Pressure | 1 | 2017 | 18 | 0.040 |
Why?
| | Maternal Health Services | 1 | 2019 | 78 | 0.040 |
Why?
| | Electrocardiography | 2 | 2010 | 563 | 0.040 |
Why?
| | Electric Impedance | 1 | 2017 | 98 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2021 | 501 | 0.040 |
Why?
| | Glucose | 1 | 2022 | 900 | 0.040 |
Why?
| | Diagnostic Imaging | 1 | 2019 | 291 | 0.040 |
Why?
| | Total Lung Capacity | 1 | 2016 | 30 | 0.040 |
Why?
| | Michigan | 1 | 2017 | 96 | 0.040 |
Why?
| | RNA | 1 | 2023 | 810 | 0.030 |
Why?
| | Bronchial Arteries | 1 | 2016 | 11 | 0.030 |
Why?
| | Causality | 1 | 2017 | 105 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 816 | 0.030 |
Why?
| | Urban Population | 1 | 2019 | 402 | 0.030 |
Why?
| | Area Under Curve | 1 | 2016 | 275 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 982 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2017 | 474 | 0.030 |
Why?
| | Cough | 1 | 2016 | 107 | 0.030 |
Why?
| | Evoked Potentials, Visual | 1 | 2015 | 30 | 0.030 |
Why?
| | Anesthetics, Intravenous | 1 | 2015 | 27 | 0.030 |
Why?
| | Evoked Potentials, Motor | 1 | 2015 | 35 | 0.030 |
Why?
| | Muscle Strength | 1 | 2018 | 271 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2016 | 298 | 0.030 |
Why?
| | Sex Characteristics | 2 | 2014 | 639 | 0.030 |
Why?
| | Automation | 1 | 2015 | 73 | 0.030 |
Why?
| | ROC Curve | 1 | 2016 | 447 | 0.030 |
Why?
| | Physical Endurance | 1 | 2016 | 231 | 0.030 |
Why?
| | Stroke | 1 | 2003 | 1015 | 0.030 |
Why?
| | Mice | 2 | 2021 | 14934 | 0.030 |
Why?
| | Gastroesophageal Reflux | 1 | 2017 | 233 | 0.030 |
Why?
| | Piperidines | 1 | 2015 | 162 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1323 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2017 | 476 | 0.030 |
Why?
| | Dyslipidemias | 1 | 2015 | 154 | 0.030 |
Why?
| | Hypercholesterolemia | 1 | 2014 | 91 | 0.030 |
Why?
| | Quality Improvement | 1 | 2021 | 953 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2019 | 2586 | 0.030 |
Why?
| | Angiography | 1 | 2013 | 177 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 4718 | 0.030 |
Why?
| | Vascular Stiffness | 1 | 2017 | 414 | 0.020 |
Why?
| | Exercise Test | 1 | 2014 | 545 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 317 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2015 | 1665 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2016 | 486 | 0.020 |
Why?
| | Gene Frequency | 1 | 2011 | 483 | 0.020 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2010 | 102 | 0.020 |
Why?
| | Median Nerve | 1 | 2009 | 20 | 0.020 |
Why?
| | Facial Paralysis | 1 | 2009 | 17 | 0.020 |
Why?
| | Intra-Abdominal Fat | 1 | 2010 | 83 | 0.020 |
Why?
| | Animals | 2 | 2021 | 31884 | 0.020 |
Why?
| | Artifacts | 1 | 2009 | 123 | 0.020 |
Why?
| | Observer Variation | 1 | 2009 | 298 | 0.020 |
Why?
| | Personality Inventory | 1 | 2009 | 134 | 0.020 |
Why?
| | Age Factors | 2 | 2007 | 2900 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 348 | 0.020 |
Why?
| | Algorithms | 1 | 2015 | 1488 | 0.020 |
Why?
| | Diabetic Neuropathies | 1 | 2009 | 79 | 0.020 |
Why?
| | Health Surveys | 1 | 2009 | 444 | 0.020 |
Why?
| | Electromyography | 1 | 2009 | 326 | 0.020 |
Why?
| | Age of Onset | 1 | 2009 | 449 | 0.020 |
Why?
| | Angiotensins | 1 | 2007 | 10 | 0.020 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2007 | 21 | 0.020 |
Why?
| | Contraceptive Agents, Female | 1 | 2008 | 65 | 0.020 |
Why?
| | Preoperative Care | 1 | 2009 | 319 | 0.020 |
Why?
| | Diabetic Retinopathy | 1 | 2009 | 149 | 0.020 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2007 | 53 | 0.020 |
Why?
| | Patient Selection | 1 | 2010 | 651 | 0.020 |
Why?
| | Self Care | 1 | 2009 | 352 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2006 | 262 | 0.020 |
Why?
| | Hospitalization | 1 | 2014 | 1754 | 0.020 |
Why?
| | Waist-Hip Ratio | 1 | 2004 | 30 | 0.020 |
Why?
| | Platelet Aggregation | 1 | 2005 | 94 | 0.020 |
Why?
| | Radiography, Abdominal | 1 | 2004 | 33 | 0.010 |
Why?
| | Age Distribution | 1 | 2005 | 341 | 0.010 |
Why?
| | Anthropometry | 1 | 2004 | 182 | 0.010 |
Why?
| | Feeding Behavior | 1 | 2009 | 574 | 0.010 |
Why?
| | Alleles | 1 | 2006 | 792 | 0.010 |
Why?
| | Neoplasms | 1 | 2016 | 2106 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2005 | 1084 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2006 | 1133 | 0.010 |
Why?
| | Risk | 1 | 2003 | 816 | 0.010 |
Why?
| | Hyperglycemia | 1 | 2003 | 294 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2006 | 1086 | 0.010 |
Why?
| | DNA | 1 | 2006 | 1353 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2009 | 2158 | 0.010 |
Why?
| | Child | 1 | 2017 | 18468 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2005 | 1006 | 0.010 |
Why?
| | Infant | 1 | 2009 | 7966 | 0.010 |
Why?
|
|
Kinney's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|